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Management of preschool children with recurrent wheezing: 
lessons from the NHLBI’s asthma research networks
Avraham Beigelman, MD, MSCIa and Leonard B. Bacharier, MDa
aDepartment of Pediatrics, Washington University and St. Louis Children’s Hospital, St. Louis, 
MO
Abstract
Recurrent wheezing in the preschool children is a common clinical problem, often associated with 
significant morbidity related to acute episodes. The management of these children has been 
complicated by a paucity of high quality clinical trials in this age group. To fill this knowledge 
gap, the NHBLI’s asthma research networks have performed a series of clinical trials in an effort 
to provide practitioners with guidance on appropriate management strategies. These studies 
establish daily inhaled corticosteroids (ICS) in toddlers at high risk for subsequent asthma as an 
effective approach for the prevention of exacerbations and symptom reduction, but without 
evidence of disease-modifying properties. Additional studies have confirmed substantial 
heterogeneity in ICS response, both in terms of efficacy and effect on linear growth. Treatment 
with intermittent high dose ICS was demonstrated to be an alternative approach to daily low dose 
ICS for preventing severe episodes in toddlers with intermittent but significant wheeze and a 
positive modified asthma predictive index. This review details the findings and clinical 
implications derived from these studies, discuss the utility of biomarkers and the role of oral 
corticosteroids during acute exacerbations, and summarizes ongoing clinical trials in this age 
group.
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Approximately 50% of children experience a wheezing illness during the first six years of 
life1, 2, and approximately one-third of young children from the US and Europe experienced 
multiple days troubled by cough, wheeze or breathlessness over the preceding six winter 
months3. The morbidity and health care utilization for these wheezing episodes in preschool-
aged children are disproportionately high, including a 50% greater rate of ambulatory visits, 
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nearly twice the rate of emergency department (ED) visits, and nearly three-times the rate of 
hospitalization compared to older children4.
Management decisions are complicated by a paucity of high quality clinical trials in 
preschool children. Given this knowledge gap, the NHBLI’s Childhood Asthma Research 
and Education (CARE) Network (1999–2009) and AsthmaNet (2009–present) have focused 
on conducting clinical trials in preschool children in an effort to provide practitioners with 
guidance on appropriate management strategies. This review summarizes the findings and 
clinical implications derived from studies done by these two networks among preschool 
children with recurrent wheezing episodes.
Early life wheezing phenotypes
Over the past 20 years, numerous studies have confirmed the clinical heterogeneity of early 
life wheezing in terms of temporal patterns (age of onset and resolution), risk factors 
(personal atopy, familial atopy, environmental exposures, intrauterine factors, genetic 
predisposition), and long-term outcomes of these phenotypes5.
The CARE Network’s first clinical trial, the Prevention of Early Asthma in Kids (PEAK) 
trial6 focused on the possibility that early treatment with inhaled corticosteroids (ICS) in 
preschool children at high risk for asthma could alter the progression from recurrent 
wheezing to asthma. In order to identify such a high risk population, the investigators used a 
modification of the Asthma Predictive Index (API)7 that was developed from the Tucson 
Children’s Respiratory Study to serve as a clinically applicable tool to identify preschool 
children with recurrent wheeze at high risk for subsequent asthma6. A positive modified API 
was present if the child had experienced at least 4 exacerbations of wheezing during the 
previous 12 months lasting more than 24h and the following major or minor criteria: one of 
the major criteria (parental physician diagnosed asthma, physician diagnosed atopic 
dermatitis, or sensitization to ≥1 aeroallergen) or two minor criteria (wheezing unrelated to 
colds, peripheral blood eosinophils ≥4%, or sensitization to milk, egg or peanut). Children 
with persistent symptomatic asthma were excluded. Detailed characterization of the 285 
children enrolled in the PEAK trial demonstrated a high prevalence of atopic features8, with 
the majority of the children (60%) having evidence of sensitization to food and/or 
aeroallergens. Male children were significantly more likely to be sensitized to aeroallergens, 
have a blood eosinophil levels of 4% or greater, or a total serum IgE level of greater than 
100 IU/mL.
A common pattern of illness in early life is recurrent severe episodes of wheezing separated 
in time by periods of asymptomatic wellness, and has been termed severe intermittent 
wheezing9. 238 preschool children participated the CARE Network’s Acute Intervention 
Management Strategies (AIMS) trial, which targeted children with recurrent episodes of 
severe wheezing with minimal-to-no wheezing outside of periods of acute respiratory tract 
illness/infection. The intermittent nature of this phenotype was reflected by infrequent 
activity limitation among these children (95% reported limitation fewer than twice per 
month), and infrequent symptoms during the 2-week study run-in period. In contrast, when 
episodes of wheezing did occur, they were frequent (71% experienced 4 or more episodes in 
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the prior year), led to health care utilization (95% with at least 1 primary care visit), ED 
visits (40%), hospitalization (8% over the past year), and oral corticosteroid use (median of 
1 course/child over the past year), confirming the severity of episodes. Children with severe 
intermittent wheezing were more often males (65%). Asthma controller use was infrequent 
among these children, with only 35% reported any controller use in the prior year. Atopic 
features were frequently present, including eczema (37%) and sensitization to aeroallergens 
(47%). A substantial proportion (60%) of these children had evidence of risk for subsequent 
asthma reflected by a positive API. Within the total population, subgroups of preschool 
children with even more severe disease were identified - children who had received oral 
corticosteroids in the previous year (60% of the cohort) had higher incidences of urgent care 
visits and hospitalizations along with higher rates of aeroallergen sensitization and a positive 
API.
Prevention of acute wheezing episodes in preschool children
Given the significant morbidity and health care burden associated with wheezing episodes 
during the preschool years, the CARE Network conducted three trials examining various 
treatment approaches towards episode prevention/amelioration (Table 1.).
The PEAK trial, conducted in 285 children 2–3 years of age with a positive modified API 
and without significant day-to-day symptom burden, was primarily designed as an asthma 
prevention trial10. The investigators hypothesized that early use of daily ICS therapy among 
high-risk children might provide disease-modifying effects and decrease asthma-related 
symptoms after the ICS were discontinued. Children were randomized to receive either daily 
ICS (fluticasone propionate 88 mcg twice daily via MDI with valved holding chamber) or 
placebo for 2 years. After 2 years, study therapy was discontinued and the children were 
followed for an additional year to determine the frequency of asthma related symptoms and 
exacerbations. The primary outcome, the proportion of episode free days (defined as days 
without asthma-related symptoms or medication use) during the 3rd year of the study, did 
not differ between treatment groups, indicating a lack of disease modifying effect of early 
initiation of ICS in high risk children. However, during the 2 years of active therapy, the 
ICS-treated group experienced significantly more episode free days compared to placebo, 
along with a significant reduction in exacerbations requiring oral corticosteroids. Thus, daily 
low-dose ICS therapy in preschool children with a positive modified API was associated 
with a significant protective effect on exacerbations during the treatment period. These 
findings provide major support for the NAEPP/EPR3 Guideline recommendation for low 
dose ICS as the preferred Step 2 therapy for preschool with a positive modified API11.
Despite the established efficacy of daily low dose ICS in increasing episode free days, 
parental adherence to such approaches in clinical care is suboptimal, likely due to the 
episodic nature of the disease in preschool children and concerns surrounding the safety of 
ICS therapy. Several small trials examined the potential clinical effect of either early use of 
oral corticosteroids or high dose ICS given at the early signs of respiratory tract illnesses 
among preschool children with severe, but episodic wheezing, with generally 
underwhelming results 12–14. The CARE Network’s AIMS trial was conducted to test the 
efficacy of early use of either high dose ICS or oral montelukast among preschool children 
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with severe intermittent wheezing15. In this year-long trial, 238 children were randomized to 
receive at the onset of specifically defined respiratory tract illnesses either high dose ICS 
(budesonide nebulization suspension 1mg twice daily for 7 days) or oral montelukast (4mg 
once daily for 7 days) or placebo, in addition to albuterol 4 times daily for 48 hours and then 
as needed. Study treatments were started when the participant experienced the signs or 
symptoms that the parents had identified as portending an impending wheezing episode. The 
primary outcome, the proportion of episode free days over the year, did not differ between 
active treatment groups and placebo, nor was there a difference in exacerbations requiring 
oral corticosteroids between treatment groups. In secondary analyses, participants with a 
positive modified API treated with either high dose budesonide or montelukast did 
experience modest reductions in symptom burden during respiratory tract illnesses.
Based upon the findings from the PEAK and AIMS trials, the CARE Network then 
conducted the Maintenance vs. Intermittent Inhaled Steroids in Wheezing Toddlers (MIST) 
trial to directly compare daily low dose ICS and episodic high dose ICS among 278 children 
12–53 months of age with a positive modified API and at least 4 episodes of wheezing in the 
past year (or 3 episodes and controllers for at least 4 months in the prior year), and at least 
one severe asthma exacerbation requiring systemic corticosteroids, urgent unscheduled, 
emergent visit or hospitalization in the past year for asthma16. Children were randomized to 
receive budesonide inhalation suspension for 1 year as either an intermittent high-dose 
approach (1 mg twice daily for 7 days, starting early during a predefined respiratory tract 
illness or as a daily low-dose approach (0.5 mg nightly), with both groups receiving 
corresponding placebos. The primary outcome for the trial, the frequency of exacerbations 
requiring oral corticosteroids, did not differ between treatment strategies, nor was there a 
difference in day-to-day symptom burden or any other clinical outcome. The intermittent 
treatment group had substantially less ICS exposure over the year than the daily ICS group 
(150mg vs 46mg). There was no difference in linear growth between the two treatment 
arms. Thus, the study was unable to discern an advantage of daily ICS over intermittent high 
dose ICS among preschool children with a positive modified API and previous 
exacerbations and with a documented history of limited impairment due to asthma16.
These three CARE Network clinical trials in preschool children at high risk for asthma, but 
without evidence of significant day-to-day impairment, that ICS therapy was effective in 
reducing exacerbations requiring oral corticosteroids, either as a daily low dose regimen or 
as an intermittent high dose regimen. These studies do not provide guidance to the preferred 
management approaches for preschool children at low risk for persistent asthma reflected by 
negative API status.
Early signs of impending exacerbations
As described above, intermittent treatment with high dose ICS, when provided early during 
the course of an evolving episode, decreases respiratory morbidity during the exacerbation. 
This treatment strategy relies upon parental recognition and identification of early warning 
signs and symptoms that precede and predict exacerbations in order to initiate the treatment 
early during the course of the episodes. Dr. Rivera-Spoljaric and colleagues investigated 
parent-reported signs and symptoms as antecedents of wheezing in preschool children in 
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order to determine their predictive capacity for the development of wheezing events17. 
Parents of participants in the AIMS trial15 prospectively identified symptoms at the start of 
respiratory tract illnesses that, in the past, would have typically been followed by a 
wheezing episode. Nasal symptoms (41%) were the most common identified symptom by 
parents as an antecedent for wheezing episodes. However, nasal symptoms had low 
sensitivity and positive predictive value for subsequent wheezing. Significant cough, which 
was less commonly reported than nasal symptom, was the most reliable predictor of 
subsequent wheezing with a specificity of 78% and a positive predictive-value of 74%. 
These findings reinforced that parents could identify specific signs and symptoms as 
antecedents of wheezing, supporting adoption of this approach in subsequent clinical trials 
of the CARE Network and AsthmaNet utilizing individualized asthma actions plans that 
include parent-reported symptom patterns as the trigger for initiation of study therapies.
Biomarkers as predictors of acute exacerbations
Biomarkers that identify children with higher risk for future asthma/wheezing exacerbations 
may allow for more targeted approaches for escalating therapy to prevent exacerbations. 
Encouraged by previous reports in the preschool age population suggesting that fractional 
concentration of exhaled nitric oxide (FeNO) may be an informative marker for asthma 
diagnosis18, 19, we investigated whether FeNO levels, measured in a subgroup of 
participants enrolled in the AIMS trial15 when the children were asymptomatic, were related 
to the risk of subsequent respiratory tract illness assessed over the following year20. The risk 
of respiratory tract illnesses, adjusted for multiple determinants of asthma severity and 
activity, was indeed significantly higher among children with baseline FeNO above the 75th 
percentile (24.4ppb) compared to children with lower FeNO levels20. In addition, FeNO 
levels >24ppb were associated with a greater number of positive skin tests to 
aeroallergens20. These findings were subsequently confirmed in 2 separate studies in 
preschool children demonstrating that FeNo levels were related to the longitudinal change in 
lung function and with the risk of future wheezing episodes21, 22.
Vitamin D levels have been reported to be inversely associated with adverse asthma-related 
outcomes among school-age children and adolescents23, 24. As limited data were available 
on the importance of serum vitamin D levels among preschool children, we investigated 
whether serum vitamin D levels <20 ng/mL (an established deficient level) were related to 
an increased rate of significant wheezing exacerbations requiring OCS25. Serum 25-
hydroxy-vitamin D levels (25-OH-VitD) were determined in samples obtained at 
randomization from 264 preschool children enrolled in the MIST clinical trial16. 18 
participants were found to be vitamin D deficient, and these participants had a significantly 
higher mean rate of exacerbations requiring OCS compared with non-deficient participants 
(1.46 vs 0.93 exacerbations/child-year, p=0.035; rate ratio, 1.56; 95% CI, 1.03–2.37). 
Analyzed as a continuous measure, vitamin D levels were not associated with significant 
exacerbations, suggesting a potential threshold effect of vitamin D level on the outcome of 
exacerbations in preschool children: serum vitamin D levels of at least 20 ng/mL may be 
adequate to attenuate the risk of exacerbations, while higher levels may not provide greater 
benefit. As a limited number of participants were vitamin D deficient, these results should 
be confirmed in a population with a higher prevalence of vitamin D deficiency. In addition, 
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an intervention trial is required to determine whether vitamin D supplements would prevent 
acute exacerbations among preschool children with episodic wheeze.
Treatment of acute severe episodic wheeze
Daily treatment with ICS is recommended in the NAEPP/EPR3 Guidelines for preschool 
children with persistent disease (with a positive modified API) or for those preschool 
children who required 2 or more courses of oral corticosteroids (OCSs) over 6 months11 as 
this approach decreases the rate of severe exacerbations requiring OCSs by approximately 
35%10. Given the occurrence of severe exacerbations despite ICS therapy, it is important to 
define an effective treatment regimen as rescue during acute exacerbations.
The NAEPP/EPR3 Guidelines11 recommend prescription of OCS for significant 
exacerbations poorly responsive to bronchodilators. Among school-aged children and 
adolescents, there is substantial evidence to support the efficacy of OCS as a treatment for 
acute asthma exacerbations26, 27. However there is limited evidence supporting this 
intervention among preschool children28, although it is standard practice to use OCS in this 
young age group. At least 3 randomized trials evaluating OCS efficacy for wheezing 
episodes in preschool children failed to demonstrate its efficacy29–31., In contrast, one 
randomized trial, performed in the ED setting, demonstrated benefit for OCS intervention 
with respect to reducing the rate of hospitalization 32. These earlier trials had substantial 
limitations including suboptimal compliance with the protocol in the largest outpatient 
study30 and relatively mild severity of exacerbations and substantial patient heterogeneity in 
the inpatient study31.
The CARE Network approached this question with a post-hoc analysis investigating OCS 
efficacy in the CARE Network AIMS and MIST cohorts of preschool children with severe 
intermittent wheezing33. Using data from the AIMS and MIST trials, we investigated the 
efficacy of a short course of OCS in more than 1500 outpatient episodes of significant lower 
respiratory tract illnesses33. OCS was a rescue treatment given based on protocol-defined 
criteria, which included presence of symptoms that did not improve after 3 albuterol 
treatments given every 15 minutes, or need for >6 albuterol nebulization treatments or >12 
puffs of albuterol by MDI for >24 hours, or moderate-severe cough for at least 5 of the 
preceding 7 days, or physician discretion with specific reason documented. All analyses 
were adjusted for baseline disease and episode severity. The results obtained in the initial 
cohort (the AIMS clinical trial15) showed that OCSs did not reduce symptom severity 
measured by symptom scores during the acute episodes, and also did not accelerate clinical 
recovery measured by the time to resolution of symptoms33. The results were confirmed in a 
validation cohort (the MIST clinical trial16), which included only preschool children with a 
positive modified API6. These findings provide post-hoc evidence that many preschool 
children with episodic wheeze may not benefit from OCS treatment. However, based on the 
post-hoc nature of the study, these results should not be directly translated to patient-care 
recommendations. Furthermore, there is an urgent need for a randomized trial that will 
investigate OCS efficacy in preschool children, particularly focusing on outpatient episodes 
and identifying if there are subgroup(s) of patients such as atopic or older preschool 
children, who may respond differently to OCS.
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Heterogeneity of ICS response: prevention of exacerbations and potential 
growth effects
A meta-analysis investigating the efficacy of daily ICS therapy for the prevention of acute 
exacerbations in preschool children with episodic wheeze/asthma concluded that ICS 
treatment resulted in fewer exacerbations requiring OCS and improvement in respiratory 
symptoms34. Treatment response was greater in studies with the inclusion criteria of asthma, 
rather than in studies that have used the inclusion criteria of intermittent wheezing. 
Moreover, there was substantial variability in ICS response between the trials, potentially a 
consequence of different asthma/wheezing phenotypes in early life. Since some of these 
phenotypes may have different responses to ICS, it would be helpful to define characteristics 
of preschool children who respond to ICS therapy. Therefore, we investigated if there were 
characteristics of preschool children that identified those most likely to benefit from ICS 
therapy among the participants of the PEAK trial, which demonstrated that daily ICS 
treatment was associated with a reduction in OCS need and with an improvement in 
symptoms during the treatment period10. The following 3 domains were associated with a 
favorable response to daily ICS treatment evident by higher number of episode free days 
and/or fewer exacerbations requiring OCS: 1) demographics: boys, whites, 2) more 
substantial disease burden as reflected by ED visits or hospitalization within the past year or 
higher frequency of asthma symptoms during the study run-in period, and (3) allergy 
features such as aeroallergen sensitization and elevated IgE levels. These findings suggest 
that ICS are most likely to produce favorable responses in preschool children who have 
these characteristics and otherwise meet criteria for daily ICS treatment as recommended by 
asthma guidelines. It is noteworthy that the characteristics associated with ICS response 
were also reflected in a greater disease burden in general, and thus identified children with 
the greatest potential to improve. However, the post-hoc nature of these findings should not 
lead to withholding ICS treatment from preschool children without these specific 
characteristics.
In addition to the heterogeneity in favorable clinical responses described above, 
heterogeneity is also evident in terms of the potential for ICS-related side effects, and more 
specifically the impact of ICS on linear growth. The PEAK clinical trial10 provided an 
excellent opportunity to explore short and long term ICS effects on linear growth in 
preschool children, as participants were treated with ICS (fluticasone propionate 176 mcg/
day) or placebo for 2 years, and then were observed for an additional 2 years. The initial 
observation on the effect of ICS on growth in this cohort was a 1.1-cm reduction in height 
gained at the end of the 2 years of treatment, caused by a delay in linear growth, compared 
with those treated with placebo10. However, after discontinuation of fluticasone therapy in 
the following year, between-group differences were no longer significant because of an 
increase in linear growth in the ICS-treated group10. However, follow-up over an additional 
year revealed that preschool children with low initial weight were more susceptible to short 
and long-term effects of ICS therapy on linear growth35. Children who were 2 years of age 
and weighed less than 15 kg at enrollment demonstrated significantly less linear growth 
during the two years of fluticasone treatment compared with the placebo group (height 
difference 1.3 cm) and these between group differences in height remained significant 2 
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years after treatment discontinuation (height difference 1.6 cm). In contrast, linear growth 
was not significantly different 2 years after treatment discontinuation in younger children of 
greater weight or older children of any weight. The authors estimated that 10mcg/kg/day of 
fluticasone propionate may represent the upper limit dose to avoid the potential long-term 
effects of daily ICS use on growth in children 2 to 3 years of age35. This was the first study 
to suggest that ICS linear growth effects in some preschool children may be less reversible, 
and reinforces the principle of using the lowest ICS dose that provides clinical benefit, and 
discontinuing ICS therapy in preschool children who do not respond.
Studies in progress
The NHLBI’s current multicenter asthma clinical research network, AsthmaNet, continues 
to investigate early life asthma and is conducting 3 clinical trials in the preschool population. 
These trials have been completed and the results should be available over the next year. 
These trials include:
1. The Effect of Early Administration of Azithromycin in Preventing Severe Lower 
Respiratory Tract Illnesses in Preschool Children (APRIL) trial. This trial evaluated 
if early administration of azithromycin, started prior to the onset of severe lower 
respiratory tract symptoms, in preschool children with recurrent severe lower 
respiratory tract illnesses, can safely prevent the progression of these episodes to 
significant episodes requiring OCS. Study population included 607 preschool 
children with a history of significant episodic wheezing. (ClinicalTrials.gov 
NCT01272635)
2. The Individualized Therapy for Asthma in Toddlers (INFANT) trial. This trial 
compared 3 treatment approaches on asthma symptom control and exacerbations: 
daily inhaled corticosteroid (ICS), daily oral leukotriene antagonist, and as needed 
ICS whenever albuterol was used for symptoms. The study also investigated 
whether differential treatment response is related to pre-defined patient 
characteristics. Study population included 230 preschool children with asthma. 
(ClinicalTrials.gov NCT01606306)
3. The Acetaminophen versus ibuprofen in children with asthma (AVICA) trial. This 
trial investigated if acetaminophen use is associated with asthma morbidity. This 
study was linked in a factorial manner to the INFANT trial (above); hence the 
study population is the INFANT study population. (ClinicalTrials.gov 
NCT01606319)
Summary
Recurrent wheezing in the preschool age group remains a challenging clinical problem. 
Research supported by the NHLBI’s asthma research networks over the past 15+ years, 
along with substantial contributions from other investigative groups, has advanced the 
knowledge base for treatment in this age group (Table 2). These studies highlight the 
necessity of age-group specific trials rather than extrapolation from studies in older children 
and provide practitioners with high quality evidence to guide treatment decisions.
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Abbreviations
AIMS Acute Intervention Management Strategies
API Asthma Predictive Index
CARE Childhood Asthma Research and Education
EFD Episode free days
FeNO fractional concentration of exhaled nitric oxide
ICS Inhaled corticosteroids
Infant Individualized Therapy for Asthma in Toddlers
MIST Maintenance vs. Intermittent Inhaled Steroids in Wheezing Toddlers
OCS Oral corticosteroids
PEAK Prevention of Early Asthma in Kids
RTI Respiratory tract illness
25-OH-VitD 25-hydroxy-vitamin D
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